Results from MiST2 suggest abemaciclib holds promise for patients with mesothelioma

The phase II MiST trial tailors treatment to the genetic make-up of mesothelioma patients who haven't responded to first-line chemotherapy. Results of arm 2 of the British Lung Foundation funded trial were presented at the American Society of Clinical Oncology (ASCO) annual meeting

Patients missing p16ink4a, a tumour suppressor, were treated with the drug abemaciclib. Abemaciclib works by blocking CDK 4 and CDK 6 proteins, which would usually be blocked by p16ink4a. The trial met its primary endpoint, disease control at 12 weeks (DCR12w) 54% (95% confidence limit (CI), 36% – 71%), with a DCR24w: 23% (95%CI, 9% – 44%). The results warrant further evaluation of abemaciclib in this patient group. Whole exome sequencing of the patient tumours is ongoing to explore resistance to treatment. To find out more, go to the ASCO website

Thanks to the Victor Dahdaleh Foundation for their support to provide funding for the MiST trial.

VDF logo

ASCO logo